Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...
Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from Stoke Therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback